Indian Journal of Pharmacology Home 

DRUG WATCH
[View FULLTEXT] [Download PDF]
Year : 2014  |  Volume : 46  |  Issue : 5  |  Page : 549--550

CYP2C9*3 polymorphism presenting as lethal subdural hematoma with low-dose warfarin

Niteen D Karnik1, Kannan Sridharan2, D Tiwari1, V Gupta1 
1 Department of Medicine, Seth Gordhandas Sunderdas Medical College and King Edward Memorial Hospital, Parel, Mumbai, Maharashtra, India
2 Department of Pharmacology, Subharti Medical College, Meerut, Uttar Pradesh, India

Correspondence Address:
Niteen D Karnik
Department of Medicine, Seth Gordhandas Sunderdas Medical College and King Edward Memorial Hospital, Parel, Mumbai, Maharashtra
India

Warfarin is the most common and cheap oral anticoagulant currently used in clinical practice. A high inter-individual variation is seen in the response to warfarin. Recently, pharmacogenetics has gained importance in managing patients on warfarin, both in predicting the optimum required dose as well as in decreasing the risk of bleeding. This case report is a description of a 49-year-old patient who had a lethal subdural hematoma with low-dose warfarin. He was subsequently found to have CYP2C9 gene polymorphism (*1/*3). This case report stresses the importance of pre-prescription assessment of genetic analysis for those initiated on warfarin.


How to cite this article:
Karnik ND, Sridharan K, Tiwari D, Gupta V. CYP2C9*3 polymorphism presenting as lethal subdural hematoma with low-dose warfarin .Indian J Pharmacol 2014;46:549-550


How to cite this URL:
Karnik ND, Sridharan K, Tiwari D, Gupta V. CYP2C9*3 polymorphism presenting as lethal subdural hematoma with low-dose warfarin . Indian J Pharmacol [serial online] 2014 [cited 2022 Nov 29 ];46:549-550
Available from: https://www.ijp-online.com/article.asp?issn=0253-7613;year=2014;volume=46;issue=5;spage=549;epage=550;aulast=Karnik;type=0